DCGI approves Bharat Parenterals Favipiravir Oral Suspension for treating Covid-19

Published On 2021-05-24 10:49 GMT | Update On 2021-05-24 10:49 GMT

Vadodara: Gujarat based pharmaceutical company Bharat Parenterals Ltd has recently announced that it has received a licence and authorization from the Drugs Controller General of India (DCGI) for the manufacture and marketing of Favipiravir oral suspension, to be used for the treatment of COVID-19 patients.

As per the filling, the product patent has already been filed under fast track approval and the company is the first one in the Indian Market to receive the license and authorization to manufacture and market "FAVIPIRAVIR ORAL SUSPENSION l00mg/ml".

Favipiravir is an antiviral agent that inhibits the RNA-dependent RNA polymerase (RdRp) of RNA viruses selectively and potently. Favipiravir was discovered through a screening chemical library for anti-viral activity against the influenza virus by Co., Ltd. Favipiravir was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.

Favipiravir undergoes an intracellular phosphoribosylation to be an active form, favipiravir-RTP (favipiravir ribofuranosyl-5′-triphosphate), which is recognized as a substrate by RNA-dependent RNA polymerase (RdRp), and inhibits the RNA polymerase activity. Since the catalytic domain of RdRp is conserved among various types of RNA viruses, this mechanism of action underpins a broader spectrum of anti-viral activities of favipiravir.

Favipiravir is a promising candidate for treating COVID-19 since it is a nucleoside analogue, according to the study.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

DCGI approves Bharat Parenterals Favipiravir Oral Suspension for treating Covid-19

Similar News

Delhi HC Refuses to Lift Ban on Medipol Pharma After Substandard Clarithromycin, Noscapine Supplied to Armed Forces

Biocon Opens First US Manufacturing Facility in New Jersey, Invests USD 30 Million in Expansion

USFDA Reappoints Vinay Prasad to Top Medical and Scientific Role

B Pharmacy Graduate Held for Operating Unauthorized Clinic in Hyderabad

No Generics for AbbVie's Rinvoq Until 2037, Analysts See Multi-Billion Dollar Boost

Advent to Sell Zentiva to Private Equity GTCR in USD 4.8 Billion Deal, Closing Expected in 2026

Chennai Court Acquits 2 After Alleged Nitravet Haul Found to Be Paracetamol

USFDA warns pharma cos to remove misleading ads